Ponatinib and axitinib are second-generation TKIs that effectively inhibit the Bcr/Abl1 signaling in CML cells with the T315I+ complex mutation.45, 46, 47 ATRA reduces DNA damage repair and inhibits the acquisition of the Bcr/Abl1 mutation during the treatment of CML, consequently reducing the adaptive drug resistance in CML.48 This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.